RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Aug 15, 2016 4:20 PM ET

Archived: Munogenics is dedicated to developing therapies for the treatment of a wide variety of cancers in both humans and animals

iCrowdNewswire - Aug 15, 2016

Munogenics, Inc. Logo

Munogenics, Inc.

Austin, TX 78753, US

Munogenics is dedicated to developing therapies for the treatment of a wide variety of cancers in both humans and animals. Munogenics is a company that has completed preliminary clinical studies prooving that certain humans do have high cancer killing activity in their immune systems and these individuals can be used to donate a certain portion of their white blood cells as an entire new concept in elminating solid tumors in individuals with cancer. This technology was orginally discovered at Wake Forest University.

It is a development stage company run by two physicians and an experienced finance professional. In addition, the Company has developed an in-vitro, patent pending assay that will determine the cancer killing activity of a person’s immune system.

The FDA has given the company an exemption of Phase I clinical trials and is now engaged in Phase II (a) clinical trials.

It is our goal that these efforts will ultimately help millions of patients worldwide regain a normal, healthy life free of cancer. We will hold
ourselves to the highest standard of integrity and work ethic in the pursuit of this goal.

Products / Services

Granulocyte InFusion Treatment

Munogenics discovered that a certain category of white blood cells, known as granulocytes, have an innate ability to kill cancer cells in cell culture. Granulocyte use is well established throughout the world. However, through the use of Munogenics’ patent pending donor assay, we uniquely possess the means of identifying donors who have granulocytes with cancer killing properties, as a prelude to Human Granulocyte InFusion Therapy (G.I.F.T.) treatment.



Chief Operating Officer
Beau Raines

Dr. Raines brings more than thirty years of experience to this position in the fields of clinical medicine and medical research. He received his DO degree at the Texas College of Osteopathic Medicine and in addition to his role with Munogenics, Dr. Raines is a private biotechnology and pharmaceutical consultant specializing in drug development, regulatory affairs and project management. He is well suited to his senior leadership role at Munogenics; having held positions of increasing responsibility in both management and research for a number of companies. He served as clinical research advisor for a well known clinical research organization (CRO) in the area of specialized oncology research programs and was project director for the development of Avastin® (Genentech) and Sutent® (Pfizer) as well as Tykerb® (GSK). Later, he took on the role of clinical director for another CRO focused on general clinical research clinical trials.

Chief Financial Officer
Robert Ainbinder

Robert Ainbinder, serves as the Company’s Chief Financial Officer. He has worked for the past 15 years as a consultant to principals seeking financing for multi-million dollar construction projects emphasizing hospitality, multi-family housing and resorts. He has also been a consultant for small emerging companies seeking public financing. Prior to that, Mr. Ainbinder was the senior partner of Robert Ainbinder & Company, a member firm of the New York stock Exchange, the American Stock Exchange, Philadelphia Stock Exchange and the Chicago Board of Option Exchange.

Chief Physician/Medical Officer
Stefini Stalos

Dr. Steffini Stalos is a Board Certified Pathologist specializing in transfusion medicine with an expertise in blood and bone marrow transfusions. She earned her DO degree at the University of North Texas Health Science Center, in Fort Worth, Texas followed by her residency in clinical pathology at UT Southwestern, in Dallas. While at UT Southwestern, Dr. Stalos was awarded a Transfusion Fellowship at the University of Minnesota and she subsequently transferred and completed her pathology residency at the University of Minnesota. She is licensed to practice medicine in both Texas and Rhode Island. In addition to having authored numerous journal articles and abstracts, Dr. Stalos is also an educator having taught at the Rhode Island Blood Center and the University of Minnesota. With her background, she will be invaluable to the Company in the area of transfusing white blood cells from donor to recipient.


Prior Year Revenue Current Year Revenue Next Year Revenue


Company Age Employees Sub-Industry
9 years 4 Biotechnology – Drugs


Company Type Stock Exchange Stock Symbol
Contact Information:

Beau Raines

View Related News >